6-(乙硫基)-2-吡嗪羧酸 | 66533-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-(乙硫基)-2-吡嗪羧酸
• 英文名称: 6-(Ethylsulfanyl)pyrazine-2-carboxylic acid
• 英文别名: 6-ethylsulfanylpyrazine-2-carboxylic acid
• CAS: 66533-64-0
• 化学式: C₇H₈N₂O₂S
• mdl: MFCD00233249
• 分子量: 184.22
• InChiKey: FRMBIAOUEAWTMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  2-Cyan-6-ethylthio-pyrazin 以70%的产率得到
  参考文献：
  名称：

  FOKS H.; JANOWIEC M.; ZIELENIECKI M., POL. J. PHARMACOL. AND PHARM., 1977, 29, NO 6, 663-673

  摘要：

  DOI：

文献信息

• HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Reddy Panduranga Adulla P.

  公开号：US20100286135A1

  公开（公告）日：2010-11-11

  The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease.

  本发明涉及公式I的新异环酰胺化合物，如本文所述或其药学上可接受的盐、溶剂化物、酯、前药或立体异构体。还公开了包含该化合物的组合物，并且公开了使用该化合物治疗或预防增殖性疾病、抗增殖性障碍、炎症、关节炎、神经或神经退行性疾病、心血管疾病、脱发、神经元疾病、缺血性损伤、病毒性疾病或真菌病的方法。
• LOW AFFINITY SCREENING METHOD
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1360489A1

  公开（公告）日：2003-11-12
• Low affinity screening method
  申请人：——

  公开号：US20040082079A1

  公开（公告）日：2004-04-29

  A parallel high throughput screening method on a solid support is disclosed that allows the detection of low affinity binding partners, comprising the steps of:(a) providing a library of different ligands;(b) forming a binding matrix comprising the ligands on a solid support by immobilising said ligands on the support; (c) contacting a target of interest with said binding matrix; (d) parallely determining a binding value of the ligand/target interaction for each type of ligand comprised in the binding matrix; (e) selecting those ligands the binding value of which in an immobilised state towards the target exceeds a predetermined threshold; (f) evaluating the affinity of each of the ligands selected in step (e) in a non-immobilised state towards the target; (g) identifying at least one ligand of step (f) as low affinity binding ligand.
• US8293747B2
  申请人：——

  公开号：US8293747B2

  公开（公告）日：2012-10-23
• [EN] LOW AFFINITY SCREENING METHOD<br/>[FR] PROCEDE DE CRIBLAGE DES FAIBLES AFFINITES
  申请人：GRAFFINITY PHARM DESIGN GMBH

  公开号：WO2002063299A1

  公开（公告）日：2002-08-15

  A parallel high throughput screening method on a solid support is disclosed that allows the detection of low affinity binding partners, comprising the steps of:(a) providing a library of different ligands;(b) forming a binding matrix comprising the ligands on a solid support by immobilising said ligands on the support; (c) contacting a target of interest with said binding matrix; (d) parallely determining a binding value of the ligand/target interaction for each type of ligand comprised in the binding matrix; (e) selecting those ligands the binding value of which in an immobilised state towards the target exceeds a predetermined threshold; (f) evaluating the affinity of each of the ligands selected in step (e) in a non-immobilised state towards the target; (g) identifying at least one ligand of step (f) as low affinity binding ligand.